The BioVault project aims to create a genomic library for over 2,300 at-risk species
Category: Health
In a bold initiative to combat the growing threat of extinction, Colossal Biosciences has partnered with the U.S. Fish and Wildlife Service (FWS) to create the "BioVault," a comprehensive genomic and biobanking archive aimed at preserving the genetic material of every species listed on the U.S. Endangered Species List. Announced on June 25, 2026, this collaboration is set to collect, sequence, and cryopreserve living cells, reproductive tissue, and DNA from over 2,300 threatened and endangered species, aiming to facilitate both species recovery and future de-extinction efforts.
Founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal Biosciences has quickly made headlines for its ambitious de-extinction projects, including efforts to revive the woolly mammoth. The company, which is currently valued at $10.32 billion, announced the partnership as a key step in its mission to build a genomic library that could serve as a reference for conservationists and scientists worldwide.
The memorandum of understandings (MOU) between the Department of the Interior and Colossal does not require any federal funding; instead, Colossal has committed to financing the project itself, with estimates of tens of millions of dollars dedicated to the BioVault. This approach allows the company to maintain control over the data generated from the project, which will be deposited into open-access repositories for free, making it available to researchers and conservationists globally.
According to the FWS, the U.S. Endangered Species List, established under the Endangered Species Act of 1973, currently includes more than 2,100 species. In the last fifty years, only 54 of these species have recovered enough to be delisted, a stark reminder of the challenges facing conservation efforts. Tragically, 67 species have gone extinct during this period, including 21 in 2023 alone. This sobering reality highlights the urgent need for innovative approaches to species preservation.
Colossal’s BioVault project aims to create a digital twin of nature, as described by Lamm, who envisions a genomic library akin to an old-school library card catalog for life. The initiative will utilize existing biobanking techniques, which involve collecting genetic material through non-invasive methods such as blood draws and skin biopsies. In certain cases, the company will also rely on opportunities presented by carcasses found in the wild or animals euthanized in cooperation with zoos, allowing for a broader range of tissue samples.
Once collected, the genetic material will be fully sequenced to create a complete digital genome. Colossal also aims to engineer some cells into induced pluripotent stem cells—blank biological slates that can differentiate into any cell type. This innovative approach is intended to identify genes associated with traits such as disease resistance and drought tolerance, which could then be used to bolster the resilience of living populations facing environmental challenges.
The BioVault project is not just about preserving genetic material; it addresses a pressing global crisis. According to the International Union for the Conservation of Nature (IUCN), approximately 48,600 species worldwide are currently threatened or endangered. The Center for Biological Diversity has projected that up to 30% of the planet’s existing genetic diversity could vanish by 2050 due to climate change, habitat loss, and pollution. The urgency of this situation is underscored by the fact that the U.S. alone has seen a concerning number of extinctions, with the FWS noting that 67 species have gone extinct under federal protection.
In this light, the BioVault serves as a proactive measure to preserve genetic diversity before it is too late. By creating an open-source biobank, Colossal and the FWS aim to empower researchers and conservationists worldwide to utilize the genetic data for various purposes, including species recovery and potential de-extinction efforts.
As the BioVault project progresses, several milestones will be key to its success. Colossal has already established a frozen biobank at its Dallas headquarters, where tissue and cell lines from roughly 200 species are stored at -274°F. The partnership with the FWS is expected to scale this effort significantly, creating a national reference library for U.S. conservation genomics.
Future developments will likely include the identification of additional species for genetic preservation and the establishment of collaborations with other research institutions and conservation organizations. As Lamm emphasized, the goal is to create a comprehensive resource that can help species adapt to changing environments and mitigate the impact of new pathogens.
Nonetheless, the initiative is not without its challenges. Collecting genetic material from endangered species is limited by the need for noninvasive methods, which may restrict the types of samples available for collection. The reliance on carcasses and euthanized animals raises ethical questions that must be navigated carefully as the project moves forward.
In the broader scope, the BioVault initiative positions Colossal as a leader in the field of conservation genomics, potentially setting a precedent for how genetic data can be used in the fight against extinction. The company’s commitment to open-access data could also inspire similar efforts in other countries and regions, fostering a collaborative approach to global biodiversity preservation.
As the world grapples with the reality of declining species populations, the Colossal-FWS partnership serves as a hopeful reminder that innovative solutions can emerge from the intersection of science and conservation. The BioVault project aims to preserve genetic diversity and to inspire a new generation of conservation efforts that prioritize both the protection of existing species and the possibility of reviving those lost to time.
With Colossal’s ambitious plans for the future, including the anticipated birth of a woolly mammoth calf targeted for late 2028, the spotlight will be on how effectively the BioVault can contribute to conservation efforts and the implications it holds for the future of endangered species worldwide.